<h2 data-section-id="1ghuy90" data-start="0" data-end="39"><strong>Generalized Myasthenia Gravis Market</strong></h2>
<p data-start="41" data-end="701">The <a href="https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market"><strong>Generalized Myasthenia Gravis (gMG) market</strong></a> is witnessing substantial growth due to rising diagnosis rates, increasing adoption of targeted biologics, and strong late-stage pipeline activity. The market size across the 7MM reached nearly USD 5.9 billion in 2025 and is projected to expand at a CAGR of 9% during 2026&ndash;2036. The US accounted for approximately 80% of the total market share, supported by favorable reimbursement and rapid uptake of novel therapies. Mechanism-specific biologics such as <span class="whitespace-normal">VYVGART</span>, <span class="whitespace-normal">RYSTIGGO</span>, and <a href="https://www.delveinsight.com/report-store/ultomiris-emerging-drug-insight-and-market-forecast"><strong><span class="whitespace-normal">ULTOMIRIS</span></strong></a> are transforming treatment paradigms.</p>
<ul data-start="703" data-end="989">
<li data-section-id="k3zv8l" data-start="703" data-end="747">2025 market size in 7MM: USD 5.9 Billion</li>
<li data-section-id="g8bz1t" data-start="748" data-end="781">Forecast CAGR (2026&ndash;2036): 9%</li>
<li data-section-id="1q0y17n" data-start="782" data-end="833">US contributed nearly 80% of total market share</li>
<li data-section-id="1yvy2yn" data-start="834" data-end="895">Growing preference for steroid-sparing targeted therapies</li>
<li data-section-id="12ft6xw" data-start="896" data-end="989">Biosimilar competition after SOLIRIS exclusivity loss may improve treatment accessibility</li>
</ul>
<h2 data-section-id="130vavf" data-start="996" data-end="1041"><strong>Generalized Myasthenia Gravis Epidemiology</strong></h2>
<p data-start="1043" data-end="1648"><a href="https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-epidemiology-forecast"><strong>Generalized Myasthenia Gravis</strong></a> is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness caused by impaired neuromuscular transmission. The diagnosed prevalent population across the 7MM was estimated at nearly 200,000 cases in 2025 and is expected to rise steadily because of aging populations, enhanced disease awareness, and improved diagnosis rates. Women represented a larger proportion of diagnosed cases in the US. Diagnostic limitations remain a challenge, particularly in ocular myasthenia gravis, where many patients are seronegative for AChR and MuSK antibodies.</p>
<ul data-start="1650" data-end="1997">
<li data-section-id="19oruap" data-start="1650" data-end="1705">Total diagnosed prevalent cases in 7MM (2025): 200K</li>
<li data-section-id="1k0mqoz" data-start="1706" data-end="1783">Regional distribution:
<ul data-start="1733" data-end="1783">
<li data-section-id="p3rw4z" data-start="1733" data-end="1744">US: 46%</li>
<li data-section-id="9wzen5" data-start="1747" data-end="1766">EU4 and UK: 43%</li>
<li data-section-id="jq5sv7" data-start="1769" data-end="1783">Japan: 11%</li>
</ul>
</li>
<li data-section-id="1decfhi" data-start="1784" data-end="1862">Gender-specific diagnosed cases in the US:
<ul data-start="1831" data-end="1862">
<li data-section-id="v3d9qv" data-start="1831" data-end="1846">Female: 60%</li>
<li data-section-id="7d83w6" data-start="1849" data-end="1862">Male: 40%</li>
</ul>
</li>
<li data-section-id="3heixf" data-start="1863" data-end="1997">Key symptoms include:
<ul data-start="1889" data-end="1997">
<li data-section-id="khaa4l" data-start="1889" data-end="1909">Drooping eyelids</li>
<li data-section-id="1pmqad5" data-start="1912" data-end="1929">Double vision</li>
<li data-section-id="clyrep" data-start="1932" data-end="1970">Difficulty swallowing and speaking</li>
<li data-section-id="66suo5" data-start="1973" data-end="1997">Respiratory weakness</li>
</ul>
</li>
</ul>
<h2 data-section-id="q204bm" data-start="2004" data-end="2045"><strong>Generalized Myasthenia Gravis Pipeline</strong></h2>
<p data-start="2047" data-end="2633">The <a href="https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-pipeline-insight"><strong>gMG pipeline</strong></a> is rapidly evolving with the development of innovative biologics, complement inhibitors, and cellular therapies aimed at improving long-term disease control and remission. Companies are focusing on targeted mechanisms to overcome the limitations of conventional immunosuppressive therapies. Emerging therapies are expected to address unmet needs such as refractory disease management, faster onset of action, and durable remission. Several late-stage candidates from leading pharmaceutical companies are anticipated to intensify market competition over the next decade.</p>
<h3 data-start="2635" data-end="2653"><strong data-start="2635" data-end="2653">Emerging Drugs</strong></h3>
<ul data-start="2655" data-end="2906">
<li data-section-id="q085de" data-start="2655" data-end="2721"><span class="whitespace-normal">Descartes-08</span> - Cartesian Therapeutics</li>
<li data-section-id="ckkcyz" data-start="2722" data-end="2774"><a href="https://www.delveinsight.com/report-store/fabhalta-drug-insight-and-market-forecast"><strong><span class="whitespace-normal">FABHALTA</span></strong></a> - Novartis</li>
<li data-section-id="mwm2z6" data-start="2775" data-end="2851"><span class="whitespace-normal">Gefurulimab</span> - Alexion AstraZeneca Rare Disease</li>
<li data-section-id="1dhwbr3" data-start="2852" data-end="2906"><span class="whitespace-normal">MAVENCLAD</span> - Merck KGaA</li>
</ul>
<h3 data-start="2908" data-end="2931"><strong data-start="2908" data-end="2931">Key Pipeline Trends</strong></h3>
<ul data-start="2933" data-end="3301" data-is-last-node="" data-is-only-node="">
<li data-section-id="1az6hto" data-start="2933" data-end="2997">Increasing focus on complement inhibition and FcRn targeting</li>
<li data-section-id="1c0j3sz" data-start="2998" data-end="3046">Expansion of oral and subcutaneous therapies</li>
<li data-section-id="1blvecj" data-start="3047" data-end="3094">Development of disease-modifying approaches</li>
<li data-section-id="1i974ml" data-start="3095" data-end="3301" data-is-last-node="">Growing investment from companies including <span class="whitespace-normal">Johnson &amp; Johnson</span>, <span class="whitespace-normal">Novartis</span>, <span class="whitespace-normal">argenx</span>, and <span class="whitespace-normal">Alexion Pharmaceuticals</span></li>
</ul>

Generalized Myasthenia Gravis Market

Generalized Myasthenia Gravis Infograhics

Generalized Myasthenia Gravis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape